Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non–Small-Cell Lung Cancer

Fred R. Hirsch, Ramaswamy Govindan, Zanete Zvirbule, Fadi Braiteh, Achim Rittmeyer, Cristóbal Belda-Iniesta, Dolores Isla, Thomas Cosgriff, Michelle Boyer, Masamichi Ueda, See Phan, David R Gandara

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Micro-Abstract We evaluated the effectiveness of onartuzumab plus first-line platinum-doublet chemotherapy in 109 patients with advanced squamous cell non–small-cell lung cancer. The patients were randomized 1:1 to receive onartuzumab or placebo plus paclitaxel/platinum. Onartuzumab did not confer any clinical benefit in the intent-to-treat population or in the MET immunohistochemistry-positive population. These findings are consistent with the published data for onartuzumab in other lung cancer studies.

Original languageEnglish (US)
Pages (from-to)43-49
Number of pages7
JournalClinical Lung Cancer
Volume18
Issue number1
DOIs
StatePublished - Jan 1 2017

Keywords

  • Immunohistochemistry
  • MET signaling
  • NSCLC
  • Poor prognosis
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non–Small-Cell Lung Cancer'. Together they form a unique fingerprint.

  • Cite this